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To foster stem cell science in South America, a collaborative meeting on scientific and bioethical aspects of
stem cell clinical translation was held in November, 2009, in Buenos Aires, Argentina, cosponsored by the
International Society for Stem Cell Research.The International Symposium on Stem Cell Research took place
from November 12–14, 2009, in Buenos Aires, Argentina. The
meeting was an initiative of the Ministry of Science, Technology
and Productive Innovation of Argentina, co-sponsored by the
International Society for Stem Cell Research (ISSCR), and orga-
nized by the Instituto Leloir and the Foundation for the Fight
Against Neurological Infant Diseases (FLENI), both from Buenos
Aires. The ISSCR previously cosponsored a regional meeting in
Shanghai, China, in 2007 and was excited to extend this para-
digm to highlight stem cell research in South America.
With talks from renowned investigators from the U.S. and
Europe alongside local investigators and a poster session offering
young investigators from the region the chance to present
their data, the meeting drew together a vibrant mix of young
students and senior researchers. The meeting focused on cardiac
and neurological diseases and incorporated a lively discussion
regarding bioethical aspects related to stem cells research
around the world and the existence of institutions offering
unapproved treatments for different human diseases using
stem cells. Finally, the meeting was the appropriate forum toArgentina leaders emphasized government commitment to support stem cell
research. Left to right: Fernando Pitossi (Instituto Leloir), Gustavo Sevlever (FLENI),
Lino Baran˜ao (Minister of Science, Technology and Productive Innovation of
Argentina), Cristina Fernandez de Kirchner (President of Argentina), Fernando Gold-
baum (Director, Instituto Leloir), GeorgeDaley (Children’s Hospital Boston), and Irving
Weissman (Stanford University).emphasize the com-
mitment of Argentina
and Brazil govern-
ments to join efforts
to strengthen stem
cell research in South
America.
A Commitment
to Science and
Technology
Participantswerewel-
comed by Fernando
Pitossi from Instituto
Leloir, Buenos Aires,
the institution that
hosted the three days
of presentations. Pi-
tossi in collaboration
withGustavoSevlever
(FLENI,Argentina)and
Jose Cibelli (Michigan
State University, USA)
organized the meet-
ing. The opening byLino Baran˜ao (Minister of Science, Technology and Productive
Innovation, Argentina) focused on aspects related to stem cell
research, the challenges for Argentina and the region, and the
need to respond to patients’ demands. His introduction to the
field was followed by Ruth Ladenheim (Secretary of Planning
and Policy in Science, Argentina) who gave an overview of
science and technology investment in Argentina. The govern-
ment is pushing to increase the investment and this needs to
be followed by private industry which is currently lagging behind.
She also stressed that a new consortium of research institutions,
medical centers and biotech companies was awarded a grant for
2.5 million U.S. dollars for stem cell research over 4 years.
Reinaldo Guimaraes (Secretary of Science, Technology and
Strategic Inputs, Ministry of Health, Brazil) provided an overview
of Brazil’s commitment to science and, in particular, to stem cell
research and training, with more than 90 groups and almost 300
PhD students working in the field. Brazil has made four calls for
grants in the stem cell research area and launched a clinical trial
of administration of bone-marrow-derived mononuclear cells to
1200 patients suffering from cardiac diseases, including cardio-Cell Stem Cell 6, 209–213, March 5, 20myopathies associ-
ated with Chagas dis-
ease (Trypanosoma
cruzi infection). The
results of this clinical
trial were described
in the meeting by the
involved researchers
(see below). The last
grant call made in
2009 aims to create
eight national techno-
logical centers that
will develop Good
Manufacturing Prac-
tice (GMP) facilities
and will provide dif-
ferent types of stem
cells to national and
foreign research
groups.
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support science and technology including stem cell research. Her
participation stressed the official support of this event. This
meeting was also an opportunity for Argentina and Brazil to
launch a new call for binational grants, with the primary objective
of performing translational research in stem cells. The agreement
was signed by Baran˜ao and Guimaraes at the end of the first day
of the meeting.
Nancy Witty (Executive Director, ISSCR) made a presentation
about the society with special emphasis on its mission: dissem-
ination and education in the field of stem cell research. A major
effort of the ISSCR is focused on ensuring rigorous standards
of clinical translation using stem cells. In this regard, she
mentioned that the ISSCR will continue to develop resources
for patients, their doctors, and advocates in evaluating stem
cell therapies. Witty cited the ISSCR’s recently published profes-
sional guidelines the Guidelines for the Clinical Translation of
Stem Cells and accompanying Patient Handbook on Stem Cell
Therapies (www.isscr.org/clinical_trans).
Bioethical Aspects of Research in Stem Cells
A round-table discussion on ‘‘regulation and ethical implications
in stem cell research and treatment’’ was held by members of
the Argentinean Advisory Committee on Stem Cell Research,
a group under the auspices of the Ministry of Science and Tech-
nology. Jorge Peralta (Hospital de Clı´nicas, Argentina, and
advisor of the INCUCAI, the National Institute of Transplants of
Argentina) gave an overview of the stem cell research field,
including major conceptual research frameworks, such as the
definition of a stem cell and the concept of pluripotency versus
multipotency, the stem cell niche, and the importance of the telo-
meres. Finally, he discussed the tremendous advances in the
stem cell field following the discovery of induced pluripotent
stem cells (iPSCs) but was cautious about the steps that should
be taken before translating this finding to the clinics. Ana del
Pozo (Hospital Garrahan, Argentina, and director of the Argenti-
nean Public National Repository for Umbilical Cords) provided
an overview of hematopoiesis and the diseases where the role
of hematopoietic stem cells (HSCs) as a therapeutic and regen-
erative tool is clearly established. Her presentation was followed
by the bioethicist Susana Sommer (University of Buenos Aires,
Argentina) who emphasized the vulnerability of patients and their
families and the way that certain clinics can take advantage of
this fact. Fabiana Arzuaga (Buenos Aires, Argentina) closed the
discussions, noting that only a few countries have regulatory
and legal frameworks for research on embryonic stem cells
(ESCs) but that most countries have guidelines.
An interesting aspect of intellectual property (IP) in stem cell
research was raised by Gabriel Kleiman (Pfizer Inc., USA). Klei-
man described the relationship between academic institutions
and companies and how it changed after introduction of the
Bayh-Dole Act (1980) that entitled North American universities
to own IP. The field is exploding with patents—more than
20,000 presented at this time—such that it is very difficult and
expensive to review all of them before a new presentation is made.
Olle Lindvall (Lund University, Sweden) presented the current
ISSCR recommendations on clinical translation of stem cell
research. He emphasized the need to establish ‘‘road maps’’
with milestones to clarify the path that will lead to the clinical210 Cell Stem Cell 6, 209–213, March 5, 2010 ª2010 ISSCRuse of stem cells. He also mentioned regulatory, ethical, and
commercial issues that need to be solved. He noted that there
are still significant gaps in our knowledge and advocated
a conservative approach in translating research to patients.
Stem cells are entirely novel products, and they are difficult to
control in terms of proliferation and differentiation. Moreover,
they can act on different cell targets, having beneficial or detri-
mental effects (such as teratomas), and may stay for a long
time in the host. Lindvall described core principles for clinical
application of stem cells articulated in the ISSCR guidelines,
including independent peer review of preclinical studies and
high standards of voluntary informed consent.
This theme was continued in a round-table discussion chaired
by Cibelli on ‘‘perspective and realities in stem cell research and
treatment.’’ George Daley (Children’s Hospital Boston, USA) reit-
erated the concern of the ISSCR regarding ‘‘stem cell tourism’’
and contrasted unregulated trials with the first U.S. Food and
Drug Administration (FDA)-approved trial for spinal cord injury
with embryonic stem cells (ESCs) that followed all the scientific
and ethical rules imposed by the FDA. Highlighting major chal-
lenges in the field, the researchers stressed the need to establish
robust preclinical data in animal models that could be replicated.
They also pointed to the need for clear protocols for stem cell
differentiation, including the need to precisely define differentia-
tion stages in order to use stem cells for organ repair, and for
study of the potential hazards of the use of stem cells, including
the potential of ESCs and iPSCs for cancer development. Finally,
it was noted that it would be unrealistic to support the idea that
stem cell treatments will have no complications in clinical prac-
tice. The panel members, citing the history of gene therapy,
advocated for prudence and caution before a decision to go to
the clinics is taken.
Panelists also discussed the apparent reluctance of large
pharmaceutical companies to enter the stem cell field, noting
that in the last 6 months there have been some hints of changes.
An aspect that needs to be resolved, according to Irving Weiss-
man (Stanford University, USA), current ISSCR President, is
the apparent absence of a clear business model to encourage
pharmaceutical companies into the field. Autologous transplan-
tation of stem cells requires the complex infrastructure of a
hospital setting and is, therefore, not a traditional off-the-shelf
pharmaceutical product. Armand Keating (University of Toronto,
Canada) and Lindvall mentioned there is a pharmaceutical
interest in the development of patient-specific iPSCs for
modeling diseases in vitro for the evaluation of their traditional
products.
Induced Pluripotent Stem Cells
In his keynote presentation, Daley reviewed the history of the
pluripotency induction screen by Yamanaka’s group that lead
to a breakthrough in the field. Since then, 3 years of dramatic
and intense work on murine and human cells has laid a solid
foundation for research into tissue formation and regeneration
using somatic cell reprogramming. Yet, Daley stressed, many
questions remain to be addressed before the use of induced
pluripotent stem cells (iPSCs) in the clinics is conceivable:
whether iPSCs are similar to ESCs, if all iPSC clones are equally
capable of reprogramming and if all diseases can be modeled.
Daley described recent collaborative studies that have followed
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entiation. Virtually all of these changes, as well as the global
remodeling of DNA methylation, are shared with ESCs, although
there remain small numbers of changes that may be specific to
iPSCs and essential for reprogramming (Doi et al., 2009). Daley
also described the heterogeneity of iPSC clones, and the failure
of many colonies to become completely reprogrammed, which
indicates that colony morphology is not a definitive parameter
to establish that an iPSC colony is fully pluripotent (Chan et al.,
2009a). They analyzed three different types of colonies by
gene expression analysis and found that complete demethyla-
tion of pluripotency genes such as OCT4 and NANOG are reli-
able surrogates for full reprogramming, but he stressed that
a definitive molecular signature of reprogramming remains
to be identified. Moreover, Daley presented data indicating
that multiple components of the telomerase enzymatic
machinery become transcriptionally upregulated during reprog-
ramming, with implications for cancer development. As an
example of how iPSCs can be used to inform disease mecha-
nisms, he reported how iPSCs derived from Down syndrome
patients show reduced angiogenesis within teratomas owing
to the extra copy of the calcineurin inhibitor DSCR1 located in
chromosome 21. The reduction in tumor-induced angiogenesis
revealed by studying iPSC may help explain the reduced lifetime
incidence of solid tumors in individuals with Down Syndrome
(Baek et al., 2009).
Gustavo Mostoslavsky (Boston University School of Medicine,
USA), described his work using polycistronic lentiviral vectors
containing the four genes initially used by Yamanaka’s group
to generate iPSC lines. Notably, 50%–70% of iPSC colonies
have a single integration site. To obtain clinical grade iPSCs
they introduced LoxP sites that allow efficient excision of the
lentiviral cassette with an adenovirus-delivered CRE. This exci-
sion of reprogramming transgenes augmented iPSC capacity
to undergo efficient differentiation in vitro (Sommer et al.,
2009). Jose Cibelli (Michigan State University, USA) presented
his data on reprogramming and telomere length. He showed
that iPSCs derived from human fibroblasts show a similar telo-
mere length to hESCs, and that this length does not appear to
be related to the age of the donor, suggesting that cells from older
people reprogram in a similar way to those obtained from young
people (Suhr et al., 2009). The next talk was by Shen Ding
(Scripps Institute, USA) who focused on the efforts by his group
to define chemical compounds that can reprogram somatic cells
in the absence of transgenes and vectors (Shi et al., 2008).
Mesenchymal Stem Cells
Pauline Conget (Universidad del Desarrollo, Chile) focused on
the possible therapeutic role of mesenchymal stem cells
(MSCs) in metabolic disorders. In animal models of diabetes,
Conget’s work demonstrated that administration of bone-
marrow-derived MSCs reverted hyperglycemia and prevented
nephropathy in diabetic mice (Ezquer et al., 2009). They also
observed that MSCs reduced hepatic infiltration of proinflamma-
tory cells protecting the liver.
Armand Keating reviewed the history of MSCs as clinical ther-
apies and mentioned that there are at least 42 clinical trials in
regenerative medicine with these cells some in acute myocardial
infarction, for a total of at least 1000 patients. Outcomes have yetto be reported for most trials. The widely accepted idea is that
MSCs generate a paracrine effect on neighboring cardiac cells
through the release of trophic factors. Keating described work
by his group where bone-marrow-derived MSCs from transgenic
mice carrying GFP driven by a cardiac-specific promoter were
cocultured with rat embryonic cardiomyocytes. About 6% of
the MSCs became GFP+ and expressed cardiomyocyte markers
but retained all the mesenchymal stroma markers tested. More-
over, the GFP-expressing MSCs did not generate action poten-
tials or display ionic currents typical of cardiomyocytes (Rose
et al., 2008). Lack of functional differentiation to the cardiomyo-
cyte lineage in his studies lends further support to the notion of
a paracrine effect. Keating also described a recent collaboration
where a new population of mesenchymal progenitor cells
(MPCs) was isolated from human umbilical cord perivascular
cells. True mesenchymal stem cells could be identified in this
population by the demonstration of self-renewal and multiline-
age differentiation in vitro and in vivo, with efficient cartilage
and bones regeneration (Sarugaser et al., 2009).
Stem Cells in Cardiology Research
Chagas disease affects almost 6 million people in Brazil, and one-
third of them will develop heart failure as a secondary
effect. Ribeiro dos Santos (Fiocruz, Brazil) described a Phase I
clinical trial approved by the national regulatory bodies in
Brazil for treating Chagas disease patients with heart failure
with intracoronary bone marrow mononuclear cells. The study
concluded that the procedure was feasible and safe with
some improvement in cardiac function (Vilas-Boas et al., 2006).
These findings led to a second clinical trial presented by Antonio
Carlos Campos de Carvalho (Universidade Federal de Rio de
Janeiro, Brazil) that was part of a multicenter trial involving 1200
patients with different cardiac diseases, including myocardial
infarction and ischemic and idiopathic cardiomyopathy. Prelimi-
nary results on the Chagas branch of this trial are not promising.
Basic research studies were presented by the next speakers.
Santiago Miriuka (Instituto FLENI, Buenos Aires, Argentina)
reviewed the different types of cardiac failures, the problem that
the area faces, and commented on their own work in under-
standing the molecular mechanisms that define the capacity of
ESCs to differentiate into cardiac cells. Michael Laflamme
(University of Washington, USA) outlined his work on the identifi-
cation of ‘‘pacemaker’’ cardiac cells following ESC differentiation.
They investigated the mechanisms of excitation-contraction (EC)
coupling in cardiomyocytes derived from hESCs, demonstrating
that they exhibited EC coupling in a similar way to adult ventricular
cardiomyocytes (Zhu et al., 2009). Finally, Jose Krieger (INCOR
Heart Institute, Brazil) described studies on cell retention and
function in the rat following different routes of administration of
labeled bone marrow cells. Random dissemination of the cells
was seen despite their administration through different routes.
Intramyocardial injection showed the most promise with further
improvement when administered with an injectable fibrin scaffold
(Nakamuta et al., 2009). They are now working with adipose-
derived MSC and demonstrated very similar data.
Stem Cell Research in Neuroscience
This session focused on strategies for the use of stem cells
in human therapy to treat neural disorders. Olle LindvallCell Stem Cell 6, 209–213, March 5, 2010 ª2010 ISSCR 211
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toxicity before progressing into the clinic and described clinical
studies using cell replacement therapy for the treatment of Par-
kinson’s disease (PD) in addition to studies investigating neuro-
genesis after ischemic stroke (reviewed in Lindvall and Kokaia,
2010).
Jose Lopez-Barneo (University of Sevilla, Spain) reviewed two
nonmutually exclusive approaches for treating Parkinson’s
disease (PD): cell replacement and use of neurotrophic factors.
He commented on their clinical work addressing the feasibility
and safety of administering carotid body (CB) glomus cell aggre-
gates in PD patients. Since most of the CB effect could be
related to GDNF expression, Lopez-Barneo’s group developed
conditional GDNF knockout mice that exhibited parkinsonian
symptoms correlating with massive neuronal cell death (Pascual
et al., 2008).
Ernest Arenas (Karolinska Institute, Sweden) then discussed
the use of human fetal tissue to treat PD. As the midbrain tissue
from at least six human fetuses was needed for the initial exper-
imental approaches to treat patients, there is a need to under-
stand the molecular mechanisms underlying dopaminergic
neuron differentiation that could eventually be applied to ESC
and iPSC research. Of particular interest, Arenas’s group studied
the Liver X nuclear receptors (LXR) and their ligands, oxysterols,
in this process (Sacchetti et al., 2009). They also observed
that blockade of wnt-1 expression increased neuronal induc-
tion and dopaminergic differentiation in embryonic stem cells
(Caja´nek et al., 2009).
Rosalia Mendez Otero (Universidade Federal de Rio de
Janeiro, Brazil) presented preclinical research using a rat model
of chronic ischemic stroke that led to a clinical trial, authorized by
Brazilian regulatory bodies, to assess safety and feasibility of
intra-arterial bone marrow cell transplantation in patients with
chronic ischemic stroke. However, they observed that cells
were retained in the area of the stroke for very short times in
most patients (Barbosa da Fonseca et al., 2010).
Phil Horner (University of Washington, USA) focused on cell
therapy for spinal cord injury. Two strategies are being evalu-
ated: either the use of neurons to fill the gaps of injured tissue
or the use of glial cells to remyelinate the affected region.
Previous reports demonstrate that adult spinal cord stem cells
are multipotent and produce neurons in vitro but mainly produce
glial cells when transplanted to the spinal cord, a clear demon-
stration of the importance of the niche. Immediately after injury,
there is a strong increase in cell proliferation, gliogenesis, and
myelin production. The scar is formed by astrocytes, but several
days later, some precursor cells differentiate to oligodendro-
cytes and start to wrap neurons (Sellers et al., 2009).
Stevens Rehen (Universidade Federal de Rio de Janeiro,
Brazil) showed the existence of aneuploidy during brain cell
development with frequent loss of chromosomes, a phenomenon
also documented during human ESC culture in vitro. His group is
currently interested in understanding the mechanisms behind
this process. Alejandro Schinder (Instituto Leloir, Argentina)
described the process of newborn neuron integration with adult
neurons. His group, in collaboration with Fred Gage’s group,
labeled dentate gyrus newborn neurons and showed that they
become fully integrated with adult neurons, established synaptic
connections and became indistinguishable from adult neurons.212 Cell Stem Cell 6, 209–213, March 5, 2010 ª2010 ISSCRFernando Pitossi (Instituto Leloir, Argentina) presented data on
the effect of prenatal inflammation on adult neurogenesis. The
results of his studies support previous work from his and others
showing proneurogenic effects of TGF-b, an anti-inflammatory
cytokine, and antineurogenic effects of proinflammatory cyto-
kines, establishing immune signals as components of the adult
neurogenic niche. Guillermo Lanuza (Instituto Leloir, Argentina)
presented data regarding neuronal specification in the devel-
oping neural tube reviewing genes involved in patterning, differ-
entiation, cycling, and migration of neurons. He focused on
a group of specialized neurons located in the spinal cord that
are recognized as central pattern generators involved in verte-
brate movements, such as walking and swimming, and are
responsible for developing locomotor circuits. His current work
is based on the role of GATA 2/3-expressing V2b interneurons.
Finally, Rau´l Russo (Instituto Clemente Estable, Uruguay) pre-
sented his work characterizing the proliferating cells in the
central canal of the spinal cord. In rats, the ependyma contains
immature cells that may differentiate to neurons and integrate
spinal circuits (Marichal et al., 2009).The Cancer Connection
The keynote lecture of the second day was presented by Irving
Weissman (Stanford University, USA), current president of the
ISSCR, on hematopoietic stem cells and cancer. Weissman
reviewed the concept of autologous transplantation of purified
CD34+/Thy-1+ HSCs free of detectable tumor contamination
after high-dose therapy for patients with advanced metastatic
breast cancer. Further work in animal models has demonstrated
that ablation is not absolutely required for donor engraftment,
explained by recent work supporting a model in which HSCs
vacate their niche in the steady state often and without dividing,
opening up space for transplanted donor HSCs without the need
for conditioning (Bhattacharya et al., 2009), suggesting new
methodologies for improving engraftment. Weissman’s talk
also touched on recent data on the role of CD47, a cell-surface
protein that protects cells from phagocytosis, in normal and
aberrant hematopoiesis. Resting HSCs do not express CD47
but do express CD47 once they mobilize and migrate: a protec-
tion mechanism exploited by leukemic cells. Blocking CD47 with
a neutralizing antibody allowed increased macrophage engulf-
ment of leukemic cells. CD47 is also highly expressed by human
bladder tumor-initiating cells, suggesting a new avenue for tar-
geting cancer stem cells (Chan et al., 2009b).
The meeting drew to a close with a final round table where,
once again, the incredible promise of stem cells was balanced
with the need for robust and reliable information before
proceeding to the clinics.REFERENCES
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